Apr 15 |
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
|
Apr 3 |
TransCode Therapeutics reports FY results
|
Apr 3 |
TransCode Therapeutics Reports 2023 Results; Provides Business Update
|
Mar 28 |
TransCode Therapeutics appoints Vlock as chief medical officer
|
Mar 28 |
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
|
Mar 11 |
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
|
Mar 6 |
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
|
Feb 20 |
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
|
Jan 31 |
Transcode Therapeutics regains compliance with Nasdaq listing rules
|
Jan 31 |
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
|